Drug Profile
Stem cell grafts - Miltenyi Biotech
Alternative Names: TCRabCD19PBSCLatest Information Update: 23 Feb 2022
Price :
$50
*
At a glance
- Originator Miltenyi Biotec GmbH
- Class Haematopoietic stem cells therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer; Haematological disorders; Immunodeficiency disorders; Metabolic disorders
Most Recent Events
- 23 Feb 2022 Discontinued - Phase-I/II for Cancer (In adolescents, In children, In adults) in Germany (IV)
- 23 Feb 2022 Discontinued - Phase-I/II for Cancer (In adolescents, In children, In adults) in Netherlands (IV)
- 23 Feb 2022 Discontinued - Phase-I/II for Haematological disorders (In adolescents, In children, In adults) in Germany (IV)